Drug Landscape ›
Coenzyme Q ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 361
Most-reported reactions
Fatigue — 46 reports (12.74%) Diarrhoea — 41 reports (11.36%) Asthenia — 39 reports (10.8%) Nausea — 39 reports (10.8%) Headache — 38 reports (10.53%) Dizziness — 35 reports (9.7%) Dyspnoea — 33 reports (9.14%) Urinary Tract Infection — 31 reports (8.59%) Eye Pain — 30 reports (8.31%) Fall — 29 reports (8.03%)
Source database →
Coenzyme Q in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Coenzyme Q approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Coenzyme Q in United States?
Sherief Abd-Elsalam is the originator. The local marketing authorisation holder may differ — check the official source linked above.